<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Ml-Systems on Athan Dial - Portfolio</title>
    <link>http://localhost:1313/tags/ml-systems/</link>
    <description>Recent content in Ml-Systems on Athan Dial - Portfolio</description>
    <generator>Hugo</generator>
    <language>en</language>
    <lastBuildDate>Fri, 09 Jan 2026 00:00:00 +0000</lastBuildDate>
    <atom:link href="http://localhost:1313/tags/ml-systems/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Preventing Metric Theater in Drug Discovery ML</title>
      <link>http://localhost:1313/case-studies/preventing-metric-theater-drug-discovery-ml/</link>
      <pubDate>Fri, 09 Jan 2026 00:00:00 +0000</pubDate>
      <guid>http://localhost:1313/case-studies/preventing-metric-theater-drug-discovery-ml/</guid>
      <description>&lt;h2 id=&#34;context&#34;&gt;Context&lt;/h2&gt;&#xA;&lt;p&gt;Data science teams were presenting accuracy metrics without reliability monitoring, creating false confidence in model predictions for multimillion-dollar compound selection decisions. The stakes were high: each compound decision represented $2M+ in development costs, but teams lacked visibility into model performance degradation over time.&lt;/p&gt;&#xA;&lt;p&gt;This work lived in the drug discovery ML platform, where prediction models guide which compounds advance to expensive in-vitro and in-vivo testing phases. My role was to own the evaluation framework design and establish decision forums with clear ownership.&lt;/p&gt;</description>
    </item>
    <item>
      <title>Scaling AI-Driven Drug Nominations from 250 to 7,000 Compounds</title>
      <link>http://localhost:1313/case-studies/scaling-ai-nominations-montai/</link>
      <pubDate>Thu, 01 Jun 2023 00:00:00 +0000</pubDate>
      <guid>http://localhost:1313/case-studies/scaling-ai-nominations-montai/</guid>
      <description>&lt;h2 id=&#34;context&#34;&gt;Context&lt;/h2&gt;&#xA;&lt;p&gt;Early 2023 presented a defining challenge: Montai&amp;rsquo;s AI models could predict activity across millions of compounds, but manual library creation processes were bottlenecked at ~250 compounds per program. The central question wasn&amp;rsquo;t whether AI could generate predictions — it was whether we could build a scalable system that maintained scientific rigor while expanding the search space 20×.&lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;Facts:&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Baseline: 100’s of compounds, chosen manually for screening from within existing library&lt;/li&gt;&#xA;&lt;li&gt;Stakes: Scale 10× to 100× per program to enabled by bioactivity ML models&lt;/li&gt;&#xA;&lt;li&gt;Environment: Early-stage biotech, unproven concept&lt;/li&gt;&#xA;&lt;li&gt;My role: First data science/product hire, architected pipeline&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h2 id=&#34;the-challenge&#34;&gt;The challenge&lt;/h2&gt;&#xA;&lt;blockquote&gt;&#xA;&lt;p&gt;How do you architect a multi-objective decision system, that provides an optimal starting point for drug discovery funnels, is understandable by all the key decision-makers at the organization?&lt;/p&gt;</description>
    </item>
  </channel>
</rss>
